# Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

> **NCT05266469** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 168 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **OTHER:** Ofatumumab
- **OTHER:** Ocrelizumab

## Key facts

- **NCT ID:** NCT05266469
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-26
- **Primary completion:** 2024-11-11
- **Final completion:** 2024-11-11
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266469, "Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05266469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*